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The purpose of High Throughput Screening (HTS) in pharmaceutical industry is to identify, as
soon as possible, compounds that are good starting points for successful new drug develop-
ment process. Experts from this area study the chemical structures of so called »hit« compo-
unds that have been found to interact with the target protein, interfere with proliferation of dif-
ferent types of cells or stop bacterial or fungal growth. Hypotheses to design related structures
with improved biological properties are than builded. Each idea is then tested by the iterative
synthesis and testing of novel compounds in various biological assays, searching for hits with
better properties and defining useful and promising »lead« molecules. In parallel, molecular
modeling and chemoinformatics experts can increase efficiency and decrease experimental
costs by using different database filtering methods. In such a way, hits from HTS may be as-
sessed before committing significant resource for chemical optimization. Joint efforts of these
HTS experimental and modeling groups are the best way to speed up the process of finding a








* Dedicated to Dr. Edward C. Kirby on the occasion of his 70th birthday.
** Author to whom correspondence should be addressed. (E-mail: donatella.verbanac@pliva.hr)
INTRODUCTION
The new century has started with the characteristics of
being landmark period for the science, medicine and drug
discovery, as well. The drugs developed over the last
four decades are targeted at about 500 different biologi-
cal targets. With the sequencing of the human genome,1
over 100,000 new biological targets will be recognized.
It has been estimated that at least 10 % of them could be
used as targets for new medicines. Over the past decade,
a variety of scientific advances and economic pressures
have driven the need for improved drug discovery scre-
ening technology.2
To increase the number of new lead molecules (mol-
ecules with promising activities), many pharmaceutical
companies made significant investment in combinatorial
chemistry and High Throughput Screening (HTS) during
1990’s. Scientific and technological advance in the ex-
perimental technology, especially in solid-state synthe-
sis, increased the number of synthesized molecules rap-
idly. Automation in HTS allows testing of hundreds or
even thousands of compounds per day. However, in spite
of the expectations, boost in the number of synthesized
and tested molecules did not increase the number of can-
didates for lead optimization. Soon, it became obvious
that additional efforts must be devoted to the design of
compound libraries.2,3
Improvements in HTS efficiency can be achieved by
applying different in silico methods. In silico screening
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(virtual screening) is a relatively inexpensive method for
identifying potential interactions among compounds and
selected targets. By in silico screening, prior to any ex-
perimental work, subset of selected compounds can be




Starting compound database is usually reduced to the re-
presentative set (RS) in order to avoid redundancy in the
chemical space, improve quality of screening library and
thus increase screening efficiency. The RS of compo-
unds is often selected through several consecutive steps
as shown in Figure 1 and briefly described in the follow-
ing text.
Preparation of Compound Database. – It is common
that compounds are present in a starting database (re-
gardless whether it is a company or commercially acqu-
ired database) in multiple forms, such as different acidic
forms, tautomers, stereoisomers or mixtures. From the
computational aspect this produces redundancy that can
cause data management problems and incorrect results.
Hence, all multicates should be removed at the beginn-
ing of the RS design. For this purpose, all original com-
pounds are written in unique standardized manner, such
as, for example, Daylight’s SMILES (Simplified Molec-
ular Input Line Entry Specification) notation.4 Such a
notation can be used in further filtering steps based only
on two-dimensional (2D) information from connectivity
tables of compounds. The »cleaning« procedure resulted
in a prepared database (Figure 1).
Depending upon the type of the starting database
and the purpose of designing RS, the prepared database
can be filtered in various ways, according to physicoche-
mical or pharmacokinetic properties, by using simple
rule-based filters to complex neutral network models. In
the case of databases composed of small molecules (Mr
< 500) in the early phase of drug discovery, the prepared
database is often filtered for drug-like compounds.
The commonly used drug-likeness filter is based on
the 2D »Lipinski rule of 5« (LR5).5 According to the
LR5, a compound that does not satisfy two or more of
the four LR5 criteria: (i) molecular weight (Mr)  500;
(ii) ClogP  5;6 (iii) number of hydrogen bond donors
(HBD)  5; (iv) number of hydrogen bond acceptors
(HBA)  10; is likely to have poor solubility and/or per-
meability and thus poor oral bioavailability. In hit- and
lead-discovery phase, the filtering borders in LR5 are
put at a lower level (e.g. Mr  400, ClogP  4, HBD  4,
HBA  8) because it is expected that during optimization
phase additional functionalities will be added.7 Filtering
based on a number of rotable bonds7,8 in molecule can
also be used in order to increase the share of drug-like
molecules in RS.
Number of compounds can be further reduced by
eliminating those with reactive functional groups and
unsatisfied absorption, distribution, metabolism, excre-
tion (ADME) and toxicity (Tox).9,10 In the ADME filter-
ing, properties such as aqueous solubility,11 human intes-
tinal absorption (HIA),12 Caco-2 permeability,13,14 and
Blood-Brain Barrier (BBB) permeability15 are often con-
sidered. The filtering borders should be quite loose since
this sifting is performed in very early stage of drug dis-
covery process, and are highly dependant on the type of
the project for which the filtering is being performed.
There are many commercially available programs for es-
timating ADME properties of small molecules (Mr < 500),
such as those in VolSurf,16 QikProp17 or C2.ADME.18
Design of Representative Set. – Filtered database, ob-
tained as described in the previous section (Figure 1), is
enriched with drug-like molecules and is further reduced
to RS for the purpose of screening, in silico or wet.
The RS can be selected in various ways using dis-
similarity based methods, partitioning or clustering.19
Regarding clustering of structurally similar compound,
various clustering techniques exist. In addition, numer-
ous distances and coefficients have been proposed and
used for similarity evaluation.20,21 Use of Daylight bina-
ry fingerprints as structural descriptors4 and Tanimoto
coefficient (TC)21 as a similarity measure is a common
practice, in spite of theirs limitations.22–24 TC has dem-
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Figure 1. The flowchart of activities in virtual screening.
onstrated its value in measuring intermolecular similar-





a b ab 
(1)
where Nab is the number of bits in common to both mol-
ecules a and b that are set to on (1); Na represents num-
ber of bits in molecule a that are set to on (1), but which
are off (0) in molecule b; and Nb is the number of bits in
molecule b that are set to on (1), but which are off (0) in
molecule a.
Two commonly used algorithms for clustering mole-
cules represented by Daylight’s fingerprints and using
TC as a measure of similarity between them are Jarvis-
-Patrick’s (J-P) algorithm25 and dbclus.26 Dbclus identi-
fies dense clusters where similarity within each cluster
reflects the TC value used for clustering. The cluster
centroids, unveiled by this algorithm, will be at least si-
milar, at the given TC value, to every other molecule wi-
thin the cluster in a consisted and automated manner.
The threshold for TC varies, dependent on the purpose
of clustering performing.
In silico Screening. – Prior to any experimental work, the
RS can be screened in silico in order to enrich it with
molecules likely to be hits for a considered target macro-
molecule.27–29 By in silico screening, the limited subset
of molecules is selected for biological testing to identify
novel chemical entities affecting a selected target mole-
cule. Such a selected subset contains significantly more
hits than a randomly chosen set. Efficiency of in silico
screening can be expressed in terms of true positive rate
(hit-rate), false positive rate and enrichment factor.29
The way of performing in silico screening depends
upon the amount of structural and other knowledge about
the target and ligands. In silico methods can be roughly
divided into 2D and three-dimensional (3D) similarity
searching approaches, ligand based pharmacophore
mapping, target based pharmacophore mapping and mo-
lecular docking and scoring. Each approach has its virtues
and shortcomings. No single in silico methods has con-
firmed generally accurate and superior to others. Hence,
different methods are often combined together in a con-
sensus way to improve efficiency of in silico screening.
Efficiency of most in silico methods depends upon
preparing compounds. In the RS, each compound is usu-
ally written in unique, standardized 2D form. It is well-
-known that different ionic species, tautomeric forms
and/or different stereoisomers of the same compound can
have significantly different binding affinities for the same
target macromolecule. Hence, prior to in silico methods,
compounds should be transferred into proper ionization
state(s), all possible tautomers or at least those that are
energetically the most preferred (degeneracy)30,31 and all
topologically and sterically possible or only the most
stable stereoisomers.32 Furthermore, for each species, a
reliable 3D structure(s) should be generated. The widely
used programs for generation of 3D structures are CON-
CORD33,34 and CORINA.35
On the other hand, results in the case of structure-
-based VS such as molecular docking and scoring36,37
depend upon a quality of 3D structure of a target macro-
molecule. Selection of target macromolecule in pharma-
ceutical industry is based on several key points: (i) ma-
cromolecule should be recognized as a therapeutic target,
and should be present in specialized databases, such as
»Therapeutic target database«;38 (ii) its X-ray structure
must be available; (iii) metabolic disorder connected to
the protein function should be described.
The preparation of target in molecular docking is in-
fluenced by the docking algorithm that is going to be
used. Special attention should be paid to hydrogen atom
positioning (hydrogen atoms are not present in crystal
structures), avoiding atomic clashes and correcting the
orientation of active-site hydroxyl-groups. In some cas-
es, water molecules that are buried in the active site play
a role in ligand-binding, and they should be kept during
the docking. As well, the metal ions can be crucial for
the target biological function and should be taken into
account in modeling of complexes between a target and
ligand in molecular docking.
In addition, efficiency of 3D VS depends very much
upon extension of structural flexibility taken into acco-
unt. Most commercially available methods treat explic-
itly flexibility of ligands. Although important, target fle-
xibility is an extremely complex problem and is usually
not explicitly taken into consideration. The docking tools
take the protein as being fixed and use its crystal struc-
ture conformation. In some docking software the hydroxyl
groups are allowed to rotate.39 However, in most state-
-of-the-art docking software FlexE40 target flexibility is
modeled by taking ensemble of various available X-ray
structures.
In VS, based on molecular docking and scoring, by
modeling complexes between a target and ligand, the
binding mode and binding affinity are predicted. The wi-
dely used docking tools include GOLD39, FlexX41 and
DOCK.42 The collection of various docking tools was
compiled by van Leeuwen43 and can be used for further
reference. It has been thought that the limitations of this
VS approach mostly come from insufficient accuracy of
scoring functions used as approximations of binding af-
finity.
In vitro Screening
Compounds Library. – The prerequisite of successful
screening process is to have good compound library.
Most drug discovery companies have created they own
compound library, although it is also possible to acquire
targeted libraries from different commercially available
sources. The employees taking care about the library are
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responsible for the compound administration (acceptan-
ce, sorting, registration and deposition) of new chemical
compounds, acquisition of synthetic compounds and nat-
ural products (Figure 2). In PLIVA – Research Institute we
have developed two brand new applications named Chem-
Client and BioClient designed with the capacity of having
efficient data handling in relation to chemical compo-
unds in general, as well as biological activity of the com-
pounds.44
The strategy of HTS is to establish a successful scre-
ening of compound libraries for new therapeutic lead can-
didates and faster definition of potential targets. The com-
plete integration of screening system is usually resolved
and set up on large-scale pipetting platforms (such as
TECAN Genesis – Figure 3). Through implementation
of robotic system technologies laboratories are capable
to increase drug-screening capacity, and to reduce con-
sumption of reagents.
Microbiology Assays. – In the field of microbiology
screening, research targets are bacterial microorganisms
such as S. aureus, S. pneumoniae, S. pyogenes, E. coli,
M. catarrhalis, H. influenzae etc. and fungi such as Sa-
charomyces cerevisiae, Candida spp. etc. Primary scre-
ening for novel compounds is done on a defined set of
microorganisms which enables to detect basic activity as
well as activity on resistant organisms carrying different
resistance genes and exerting the resistance by several
mechanisms.
Strains are cultured on Miller-Hinton agar (Merck,
Germany) except strains belonging to genus Streptococ-
cus and Haemophilus which are cultured on blood agar
plates (Biomerioux, France) and chocolate agar plates
(Biomerioux, France), respectively. Minimum inhibitory
concentration (MIC) is determined by the microtitre liq-
uid dilution method (Figure 4) as described is standard
operation procedure,45 except that for Streptococcus me-
dium. Read out is carried out by eye inspection and min-
imal inhibitory concentration (MIC) is expressed as low-
est concentration showing 90 % of inhibition of control
growth.
Cytotoxicity Screening. – Cytotoxicity screening of novel
compounds with a defined set of standard cell lines
(THP-1, COS, Hep G-2, CHO, A549, H 292, PLB 985,
COR-L23, COR-L23R, COR-5010, HL-60, MIA-Pa-
-Ca-2, HeLa) enables to detect basic possible cytotoxi-
city effect of novel substances.46 Principle of testing is
that cells in phase of growth are exposed to a drug. The
cells are allowed to proliferate in order to distinguish be-
tween cells that remain viable and are capable of prolif-
eration and those that remain viable but cannot proliferate.
Measuring the succinate dehydrogenase mitochon-
drial activity of living cells by specific reagent 3-(4,5-
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Figure 2. Compounds deposited in the vials in the storage.
Figure 3. TECAN Genesis 200 Robotic system in HTS Unit. Figure 4. Layout of the plates in HTS-MIC screening.
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) the amount of viable cells can be detected (Sche-
me 1). The enzyme turns the MTT into a brown color by
cutting the tetrazolium ring. The amount of produced
MTT-Formazan can be determined spectrophotometri-
cally at 490 nm.47
Another approach is used in order to establish anti-
-proliferation assays of human or animal blood cells and
other primary cell lines – bioluminescent adenosine tri-
phosphate (ATP) cytotoxicity screening. This type of
screening is intended for the rapid and safe detection of
proliferation and cytotoxicity of mammalian cells and
cell lines in culture by determination of their ATP levels.
ATP can be used to assess the functional integrity of living
cells since all cells require ATP to remain alive and carry
out their specialized functions.48 The bioluminescent me-
thod utilizes an enzyme, luciferase, which catalyses the
formation of light from ATP and luciferin according to
the following reaction (Scheme 2). The emitted light in-
tensity is linearly related to the ATP concentration and is
measured using a luminometer or beta counter. The as-
say is conducted at ambient temperature.49
Enzymatic Screening. – Influence on the compounds
on particular enzyme (kinase, peptidase, transferase, li-
gase…) can be also successfully measured in HTS Unit.
Detection techniques depend on type of assay designed
for the particular enzyme. In high-throughput format en-
zyme activity can be detected measuring absorbance,
fluorescence, luminescence and fluorescence polarizati-
on.50
Enzyme-Linked Immunosorbent Assay (ELISA)
Assay51 for determination of different enzyme activity is
a widely method. Usually microtitar plates are coated
with the substrate and during the reaction competition of
the compound and specific substrate for the active site of
the enzyme can give the answer on specific activity.
Gene Expression Analysis (Microarrays). – Transcrip-
tional profiling DNA microarray technique (gene chips)
is a relatively new technology. It promises to monitor
the whole genome on a single chip. In that way research-
ers can have a »global« picture about the interactions be-
tween the compound (lead) and thousands of genes rele-
vant for the noteworthy disease. The remarkable power
of DNA microarrays already has a strong impact on me-
dicine: in the molecular characterization of diseases, drug
discovery and evaluation of results. It is to be expected
that quantitative applications will soon spread through
all fields of life sciences.52
Data Processing and Visualization. – As a systematic
response to the challenges of data explosion in biomedi-
cal sciences, pharmaceutical research should establish its
own informatics solution that will be capable of harness-
ing the power behind the tidal waves of information
sweeping through the drug discovery process. Clustering
and dimensional reduction techniques are nowadays used
for additional representation of specific and mostly com-
plex relationships among chemical properties and biolo-
gical activity. Such techniques are putting an emphasis
on novel visualizations tools with the attempt to create a
system for the automated deduction of important drug-
-target relationships.
CONCLUSION
In the past four decades about 500 therapeutically rele-
vant targets have been recognized. Today, with the com-
pletion of the human genome it is expected that about
100,000 new protein structures will be recognized. Not
all of them will be used in developing new therapies, but
experts estimate that at least 10 % will be most likely
declared as promising therapeutic targets, meaning that
their activity can be modulated by external compounds
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Scheme 2. Bioluminiscent reaction used in Bioluminiscent ATP Cytotoxicity assay.
(emmission at 565 nm)
and used in the treatment of different diseases. Such an
increase of proteins is accompanied by extreme increase
of synthesized small molecules, coming from commer-
cial or proprietary databases (which is partially a result
of the efforts in combinatorial synthesis).
This results in a combinatorial problem of many tar-
gets to which many molecules can be applied and a fast
and effective solution is required to solve it. The results
obtained by implementing an multidisciplinary approach,
combining in silico screening with in vitro experiments
(HTS), have shown that it represents the best way to get
accurate results in a very short time period, in reagent-
-saving manner.
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SA@ETAK
Kombinirani in silico i in vitro pristup pronala`enju spojeva s mogu}im ljekovitim djelovanjem
Donatella Verbanac, Dubravko Jeli}, Vi{nja Stepani}, Iva Tati}, Dinko @iher i Sanja Ko{trun
Svrha HTS-a u farmaceutskoj industriji je identifikacija spojeva koji mogu poslu`iti kao dobre polazne
molekule u procesa razvoja lijeka iz novih kemijskih entiteta. Prou~avanjem kemijske strukture takvih »hit«
spojeva koji interagiraju s proteinom – metom, stru~njaci iz tog podru~ja tragaju za strukturama pobolj{anih
biolo{kih svojstava. Svaka se ideja kasnije provjerava iterativnim postupkom sinteze i testiranja novih spojeva
uporabom razli~itih metoda biolo{kih probira, kako bi se do{lo do hitova s boljim svojstvima i do uporabivih i
obe}avaju}ih »lead« molekula. Istovremeno, molekularno modeliranje i kemoinformatika mogu pove}ati u~in-
kovitosti i smanjenja tro{kova eksperimenata uporabom razli~itih metoda filtriranja baza spojeva. Na taj na~in,
»hitovi« iz HTS-a mogu virtualno biti procijenjeni prije zna~ajnog ulaganja resursa u kemijsku optimizaciju.
Udru`eni napori eksperimentalnih HTS grupa i grupa koje se bave molekularnim modeliranjem najbolji su na-
~in ubrzavanja procesa pronala`enja novih, uporabivih »hitova« i obe}avaju}ih »leadova«.
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